Supplementary Figures
Expected percent heritability explained versus number of risk loci contributing to the genetic component: (A) for the discovery cohort at significance thresholds 5e-8 (genomewide significance), 5e-6 (correction for testing 10,000 independent loci), 5e-5 (correction for testing 1,000 independent loci) and 5e-4 (correction for testing 100 independent loci), and including expected AUROC corresponding to the percent heritability explained (y-axis, right), and (B) for various sample sizes assuming a genomewide significance cutoff of 5e-8 for inclusion in the model. Expected percent heritability explained is computed assuming population prevalence of 0.217 and heritability (h 2 ) of 0.18 as estimated from the discovery cohort. Number of Risk Loci Expected Percent Heritability Explained n = 2,706 n = 10,000 n = 25,000 n = 50,000 n = 75,000 n = 100,000
Sample Size:
Supplementary Figure 2:
Final versus leaderboard performance. Collaborative phase leaderboard score versus final submission score for AUPR, AUROC for the classification subchallenge, and correlation for the quantitative subchallenge with linear regression fit and 95% confidence region (shaded). While the two metrics for the classification subchallenge showed positive correlation (r= 0.71 and 0.60 for AUPR and AUROC, respectively) between the scores on the leaderboard data, which is a held-out portion of the training dataset, and the scores on the test data, the quantitative prediction subchallenge showed a negative correlation (r= -0.052) suggesting a tendency toward overfitting in that subchallenge. • 
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Team SBI_Lab
The aim of team SBI_Lab's study was to identify candidate SNPs playing a role in the response to therapy in RA patients by compiling several sources of information. To account for the imbalance between the number of SNPs and the number of patients, they performed a feature selection procedure on the genetic data. First, SNPs were mapped to genes using the Ensembl Variation database 2 and BIOMART service 3 . SNPs that could not be mapped to a gene were discarded. Second, SNPs were prioritized based on association and correlation measures between SNP dosage and patient responses, independently for each drug. The list of candidates was expanded using gene-priorization algorithms that combined proteinprotein interaction networks and expression data. The procedure is based on the guilt-byassociation principle 4 
Team Lucia
Team Lucia selected SNPs in two independent steps, based on prior biological knowledge and on statistical criteria. 242 genes were selected from literature that were known to play a role in the development of RA, or to be targets for the drugs used in the considered treatments 9, 10 . All SNPs within 10kb upstream and 1 kb downstream of the selected genes, as well as those located in their distant enhancer sequences 11, 12 , were included. Among these SNPs, those located in introns were discarded. This led to a list of 3,840 SNPs selected on available biological data. SNPs were also ranked by mutual information and the top 3000
were selected for each treatment. teams, as features. The optimal model set all SNP coefficients to zero using cross validation, which is equivalent to regularizing out (removing) the contribution of all genetic variants from our final genetic model.
Team STSI
We used a tree-based regression model, known as cubist regression 17 (ii) a Bayesian efficient multiple kernel learning method BEMKL 20 . GEMMA enables modelling of a mixture of a small number of large genetic effects and a large number of small random genetic effects. The BEMKL model encodes the information from different data sources into kernels, and integrates the kernels for the prediction by learning kernel weights and sample weights across different samples. In GEMMA prediction, the SNP data were first projected to make these predictors linearly independent of the clinical variables.
In BEMKL prediction, Kronecker delta kernels were used for the categorical features and
Gaussian kernels for the other predictors.
Team wtwt5237
According to existing literature, 18 MTX response related SNPs, 124 anti-TNF drug response related SNPs, 78 RA-related SNPs, and 20,385 immune-related SNPs were selected.
Principal components (PCs) of RA-related SNPs were calculated by PCA. PCs of all SNPs and immune-related SNPs were calculated by PLINK 21 . For both sub challenges, 5 different algorithms were trained, which include randomForest (alg1), LASSO 22 (alg2), SVM (alg3), Adaboost (alg4) and PLS (alg5). For the quantitative subchallenge, we predicted final DAS28 levels for alg1, alg3 and alg5, and calculated ΔDAS28 by subtracting baseline DAS28 from the predicted final DAS28 levels. In each of the 5 algorithms, we included baseline DAS28, age, gender and MTX usage. Additionally, anti-TNF treatment is used as a covariate for alg1, alg3, and alg4, but for alg2 and alg5, patients were stratified according to the anti-TNF drugs used and made drug-specific training and prediction. Two novel drugs, certolizumab and golimumab, were modeled as adalimumab and infliximab, respectively, according to similarities of these compounds. In addition, team wtwt5237 included different combinations of SNP sets or the first 3-70 PCs of immune-related, RA-related or all SNPs in the machine learning algorithms. Finally, predictions from the 5 algorithms were combined using different weights.
